Katja Weisel, MD of Janssen Oncology gives an overview of her abstract, which focuses on two randomized phase III trials in relapsed or refractory multiple myeloma. DRd (POLLUX) or DVd (CASTOR) significantly improved PFS and deepened responses compared with Rd or Vd alone. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Advertisement